ICIs targeting checkpoint proteins such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) have demonstrated anti-tumor response in HCC [3,4,5,6]. The gene discussed is PDCD1; the disease is neoplasm.